20Dec 2018

AN ANALYTICAL STUDY TO COMPARE MATERNAL OUTCOMES WHEN MGSO4 THERAPY AFTER LOADING DOSE IS CONTINUED TO 12 HOURS INSTEAD OF 24 HOURS IN SEVERE PREECLAMPSIA AND ECLAMPSIA.

  • Department of Gynecology and Obstetrics.Institute of Post-Graduate Medical Education and Research,A.J.C. Bose Road, Kolkata-700020, West Bengal, India.
Crossref Cited-by Linking logo

Plum Print visual indicator of research metrics
  • Captures
    • Readers: 3
see details

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Pregnancy Induced Hypertension (PIH) develops due to pregnancy and regresses after delivery. It is a known cause of premature delivery, intrauterine growth restriction, placental abruption, foetal death and numerous adverse pregnancy outcomes. Maternal complications like oliguria, eclampsia, hemolysis, thrombocytopenia, elevated liver enzymes, pulmonary edema and even death. Previous history of preeclampsia, pre-existing diabetes, obesity, multiple pregnancies has been reported to increase the risk of pregnancy induced hypertension and pre-eclampsia. The aim of the present study was to determine whether decreasing the duration of the MgSO4 regimen to 12 hours instead of 24 hours after the last fit in improving maternal outcome in pre-eclampsia and eclampsia. In the present prospective randomized study, women with severe pre-eclampsia and eclampsia admitted in Department of Obstetrics and Gynecology at IPGME&R, Kolkata, India, was enrolled between April, 2016 to March 2017, selecting the patients on the basis of inclusion and exclusion criteria. Early stoppage of this toxic drug administration which needs constant monitoring in a busy labor room is definitely a major advantage. The shorter postpartum administration of MgSO4 also has the advantages of early ambulation, early removal of urinary catheter and early resumption of nursing of baby and other daily activities with lesser risk of MgSO4 toxicity. The study therefore concludes that the use of short duration postpartum MgSO4 therapy for 12 hours instead of 24 hours with continued hourly maternal monitoring of vital signs.

  1. James P, Nelson-Piercy C, Management of hypertension before, during and after pregnancy Heart, Vol.90 No.12. pp 1499-1504.
  2. Duley L. The global impact of pre-eclampsia and eclampsia. Seminars in Perinatology, 2009 Jun;33(3):130?137.
  3. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet, 2010, 21;376(9741):631?44.
  4. Khan KS, Wojdyla D, Say L, G?lmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet, 2006 Apr 1;367(9516):1066?1074.
  5. Magee LA, Pels A, Helewa M, Rey E, vonDadelszen P, Hypertension Guideline C: Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J ObstetGynaecol Can 2014,36(5):416?441.
  6. Dutta DC. Hypertensive disorders in pregnancy, In:Textbookof Obstetrics, Ed. Konar HL editor, 8th edition.Kolkata: New Central Book Agency, pp.256, 2015.
  7. Osungbade KO, Ige OK: Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. J Pregnancy 2011, 2011:481095.
  8. World Health Organization. The World Health Report.Life in the 21st century; a vision for all. Geneva: WHO 1998, pp.97,1998.
  9. ACOG practisebulletin.Diagnosis and management of preeclampsia and eclampsia. Number 33,January 2002. ObstetGynecol 2002;99;159-67.
  10. Duckitt K, Harrington D: Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005,330(7491);565.
  11. OwireduWKBA,AhenkorahL,TurpinC,AmiduN,LaingEF.Putative risk factors of pregnancy induced hypertension among Ghanian pregnant women.J Med Biomed Sci 2012,1(3):62-76.
  12. Williams Obstetrics, Cuningham, Leveno, Bloom,Spong, Dashe, Hoffman, Casey, 24 edition..
  13. Arias' Practical Guide to High-Risk Pregnancy and Delivery,A South Asian Perspective by AmarnathBhide,SabaratnamArulkumaran,Kaisad R Damania,Shirish N Daftary,4th Edition.
  14. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Preeclampsia. Lancet. 2010;376:631- 44
  15. Fontenot MT, Lewis DF, Fredrick JB, Wang Y, Deframo EA. A prospective randomized trial of magnesium sulphate in severe preeclampsia: use of dieresis as a clinical parameter to determine the duration of postpartum therapy. Am J Obstet Gynecol. 2005;192:1788-94
  16. Sibai BM, Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials, Am J Obstet Gynecol. 2004 Jun;190(6):1520-6.
  17. World Health Organization. WHO recommendations for Prevention and treatment of pre-eclampsia and eclampsia.http://whqlibdoc.who.int/publications/2011/ 9789241548335_eng.pdf.Published 2011.Accessed February 4, 2012.
  18. Duley L, G?lmezoglu AM, Henderson-Smart DJ, Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst Rev 2010;11:CD000025.
  19. Noronha Neto C, de Souza ASR, Amorim MMR. Pre-eclampsia treatment according to scientific evidence. Rev Bras GinecolObstet 2010;32(10):459?68.
  20. ACOG Committee on Practice Bulletins?Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. ObstetGynecol 2002;99(1):159?67
  21. Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J ObstetGynecol 2004;190(6):1520?6
  22. World Health Organization. Managing Complications in Pregnancy and Childbirth: A guide for midwives and doctors. http://whqlibdoc.who.int/publications/2007/ 9241545879_eng.pdf .Published 2003. Accessed February 4, 2012
  23. Isler CM, Barrilleaux PS, Rinehart BK, Magann EF, Martin Jr JN. Postpartum seizure prophylaxis: using maternal clinical parameters to guide therapy. ObstetGynecol 2003;101(1):66?9.
  24. Ascarelli MH, Johnson V, May WL, Martin RW, MartinJr JN. Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for pre-eclampsia. Am J ObstetGynecol 1998;179(4):952?6.
  25. Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2010;4: CD007388
  26. Conde-Agudelo A, Belizan JM, Diaz-Rossello J. Kangaroo mother care to reduce morbidity and mortality in low birthweight infants. Cochrane Database Syst Rev 2011;3: CD002771.

[Sumit Ranjan Pramanik, Saumen Mandal, Subrata Mandal and Debarshi Jana. (2018); AN ANALYTICAL STUDY TO COMPARE MATERNAL OUTCOMES WHEN MGSO4 THERAPY AFTER LOADING DOSE IS CONTINUED TO 12 HOURS INSTEAD OF 24 HOURS IN SEVERE PREECLAMPSIA AND ECLAMPSIA. Int. J. of Adv. Res. 6 (Dec). 1078-1085] (ISSN 2320-5407). www.journalijar.com

Dr. Debarshi Jana
Department of Gynecology and Obstetrics Institute of Post-Graduate Medical Education and Research, A.J.C. Bose Road, Kolkata-700020, West Bengal, India

DOI:

Article DOI: 10.21474/IJAR01/8238      
DOI URL: https://dx.doi.org/10.21474/IJAR01/8238

Download Full Paper

Download PDF No. of Downloads: 40 | No. of Views: 103